Compare Novo Nordisk A/S (NVO) vs Synchrony Financial (SYF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Synchrony Financial — how do they compare? Novo Nordisk A/S trades at $38.38 (market cap $165.31B), while Synchrony Financial trades at $72.94 (market cap $23.99B). The key difference: Novo Nordisk A/S is far larger — about 6.9× Synchrony Financial's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Synchrony Financial for 28 Days on average.
| NVO | SYF | |
|---|---|---|
Market Cap | $165.31B | $23.99B |
Volume | 11,432,838 | 3,813,027 |
Sector | Health | Financials |
52-Week High | $63.98 | $88.47 |
52-Week Low | $35.29 | $63.78 |
Typical Hold Time | 116 Days | 28 Days |
Enterprise Value | $179.56B | $24.23B |
Dividend Yield | 4.71% | 1.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Synchrony Financial (SYF) trades at $73.16, up 1.71% on the day, with a bullish technical signal despite some bearish moving averages. The stock shows strong fundamentals, with a low P/E of 7.56 and robust profitability, including a 23.4% net income margin and 22.23% ROE. Recent earnings have consistently beaten expectations, and the company is expanding through partnerships like the recent tie-up with Vetspire and OpenAI.
The outlook is positive, supported by analyst consensus with a $87.58 price target and 61% buy ratings. Key opportunities include high receivables growth and strategic AI integrations, while risks involve increased investing cash outflows and potential consumer credit stress amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
